In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...

In October of this year, at just thirty years old, Katie Wygel was diagnosed with Acute Myeloid Leukemia. Since then, she’s ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Forskolin, a plant-derived compound, shows surprising potential against one of the most aggressive forms of leukemia.

Removing etoposide did not negatively affect OS, DFS, MRD, or relapse rate at 3 years for pediatric patients with LR1, LR2 or high-risk AML.

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

Acute myeloid leukemia (AML) is a rare, fast-growing cancer that starts in the bone marrow. The disease promotes the ...

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...